AstraZeneca’s Tagrisso Shows Promise Across Lung Cancer Stages at ELCC 2025

New findings from the European Lung Cancer Congress (ELCC) 2025 highlight AstraZeneca’s Tagrisso (osimertinib) as a leading therapy for EGFR-mutated non-small cell lung cancer (NSCLC). The data, presented between March 26-29, showcase Tagrisso’s effectiveness as both a monotherapy and as a foundation for novel combination treatments across various stages of EGFRm NSCLC. Key trials include LAURA (Phase III), which demonstrates Tagrisso’s impact in unresectable Stage III NSCLC post-chemoradiotherapy, and FLAURA2 (Phase III), which supports its role in first-line treatment when combined with chemotherapy. Additional studies, such as SAVANNAH and ORCHARD, explore combinations with Orpathys (savolitinib) and Datroway (datopotamab deruxtecan) to address disease progression in advanced cases.

Leading experts emphasize that Tagrisso not only extends overall survival but also helps maintain quality of life, a crucial factor in lung cancer care. Dr. Myung-Ju Ahn of Samsung Medical Center highlighted the drug’s role in addressing disease progression while preserving patient well-being. Susan Galbraith, AstraZeneca’s EVP of Oncology R&D, emphasized that with over one million patients treated globally, Tagrisso continues to transform lung cancer expectations. Patient advocates, including Professor Virginia Harrison of EGFR Positive UK, also welcomed these advancements, stressing the importance of effective yet tolerable treatments. As lung cancer research progresses, Tagrisso remains a cornerstone therapy, offering renewed hope for patients worldwide.